Sildenafil

Generic Name: Sildenafil

Brand Names: Liqrev, Revatio, Viagra, Vizarsin, Sildenafil Actavis, Sildenafil ratiopharm, Granpidam, Sildenafil Teva, Mysildecard

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₀N_₆O_₄S

CAS Number: 139755-83-2

Unique Ingredient Identifier: 3M7OB98Y7H

Background: In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently faci...

Indication: Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:

(1) the treatment of erectile dysfunction ; and

(2) treatment of pulmonary hypertension, where:
...

Associated Conditions: Erectile Dysfunction, NYHA Functional Class II-III Pulmonary arterial hypertension, Premature Ejaculation, Pulmonary Arterial Hypertension (PAH)

Associated Therapies: -

Clinical Trials

Sildenafil IV Bolus Study

Phase 1

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: sildenafil

First Posted Date: 2008-12-02

Last Posted Date: 2021-02-01

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 12

Registration Number: NCT00800592

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.

Phase 1

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Sildenafil

First Posted Date: 2008-11-21

Last Posted Date: 2021-02-01

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 18

Registration Number: NCT00795938

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure

Phase 4

Withdrawn

Conditions: Heart Failure

Interventions: Drug: Sildenafil

First Posted Date: 2008-11-19

Last Posted Date: 2023-06-26

Lead Sponsor: University of New Mexico

Registration Number: NCT00793338

Locations: 🇺🇸
Clinical Translational Science Center, Albuquerque, New Mexico, United States

Effects of Viagra on Heart Function in Patients With Heart Failure

Phase 4

Completed

Conditions: Heart Failure
Left Ventricular Dysfunction

Interventions: Drug: sildenafil
Other: Placebo

First Posted Date: 2008-10-29

Last Posted Date: 2014-07-02

Lead Sponsor: MetroHealth Medical Center

Target Recruit Count: 10

Registration Number: NCT00781508

Locations: 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension

Phase 3

Withdrawn

Conditions: Hypertension, Pulmonary

Interventions: Drug: Sildenafil

First Posted Date: 2008-10-28

Last Posted Date: 2009-11-13

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00780728

Taste Test of a New Formulation of Sildenafil (Revatio)

Completed

Conditions: None Volunteer

Interventions: Drug: sildenafil

First Posted Date: 2008-10-08

Last Posted Date: 2021-02-01

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 4

Registration Number: NCT00768573

Locations: 🇺🇸
Pfizer Investigational Site, Cambridge, Massachusetts, United States

Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Sildenafil

First Posted Date: 2008-10-01

Last Posted Date: 2014-07-23

Lead Sponsor: Duke University

Target Recruit Count: 216

Registration Number: NCT00763867

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of Utah Health Sciences Center, Murray, Utah, United States

and more 7 locations

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: placebo
Drug: sildenafil
Drug: paclitaxel (taxol)
Drug: carboplatin (palaplatin)

First Posted Date: 2008-09-15

Last Posted Date: 2011-09-07

Lead Sponsor: Hamamatsu University

Target Recruit Count: 120

Registration Number: NCT00752115

Locations: 🇯🇵
Hamamatsu University School of Medicine, Hamamatsu, Japan

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

Phase 2

Completed

Conditions: Sexual Dysfunctions, Psychological
Sexual Arousal Disorder

Interventions: Drug: sildenafil

First Posted Date: 2008-09-04

Last Posted Date: 2021-02-01

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 267

Registration Number: NCT00746967

Locations: 🇺🇸
Pfizer Investigational Site, Cheyenne, Wyoming, United States

The Assessment of Right Ventricular Contractility in Response to Sildenafil

Phase 3

Terminated

Conditions: Hypertension

Interventions: Drug: Sildenafil

First Posted Date: 2008-08-27

Last Posted Date: 2021-04-19

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 10

Registration Number: NCT00742014

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy